Department of Emergency Medicine and Chest Pain Center, Qilu Hospital, Shandong University, Jinan, China.
Key Laboratory of Cardiovascular Remodeling and Function Research, Ministry of Education and Ministry of Public Health of People's Republic of China, Qilu Hospital, Shandong University, Jinan, China.
J Cell Mol Med. 2018 Apr;22(4):2518-2522. doi: 10.1111/jcmm.13536. Epub 2018 Feb 14.
Aldehyde dehydrogenase 2 (ALDH2) Glu504Lys variant was an independent risk factor for acute coronary syndrome (ACS). However, there are lacking researches about the relationship between the variant and prognosis of ACS. In the prospective study, 377 ACS patients were grouped into the wild-type (*1/*1) and the mutation (*2/*2 + *1/*2) groups according to genotype detection. Compared with the wild-type group, incidences of major adverse cardiac events (MACE) and cardiac death were both higher in the mutation group (9.2% vs 21.0%, P = .002; 5.2% vs 12.2%, P = .026); the MACE-free and the cardiac-death-free cumulative survival rates were obviously lower in the mutation group. Moreover, the mutant genotypes were associated with significantly increased risk of MACE and cardiac death (HR 2.443, 95%CI: 1.390-4.296, P = .002; HR 2.727, 95%CI: 1.303-5.708, P = .008). These results suggested that ALDH2 Glu504Lys variant could predict a worse prognosis of ACS patients.
乙醛脱氢酶 2（ALDH2）Glu504Lys 变体是急性冠状动脉综合征（ACS）的独立危险因素。然而，关于该变体与 ACS 预后之间的关系还缺乏研究。在这项前瞻性研究中，根据基因型检测，将 377 例 ACS 患者分为野生型（*1/*1）和突变型（*2/*2+*1/*2）组。与野生型组相比，突变型组主要不良心脏事件（MACE）和心脏死亡的发生率均较高（9.2%比 21.0%，P=0.002；5.2%比 12.2%，P=0.026）；突变型组的 MACE 无事件和心脏死亡无事件累积生存率明显较低。此外，突变基因型与 MACE 和心脏死亡的风险显著增加相关（HR 2.443，95%CI：1.390-4.296，P=0.002；HR 2.727，95%CI：1.303-5.708，P=0.008）。这些结果表明，ALDH2 Glu504Lys 变体可预测 ACS 患者的预后较差。
